Kyowa Kirin seeks added indication for Lumicef in Japan

8 January 2020

Japanese drugmaker Kyowa Kirin (TYO: 4151) today said that it has submitted a supplemental application for Lumicef (brodalumab) for the treatment of axial spondyloarthritis (axSpA) in Japan.

The supplemental application is based on the result of a Phase III clinical trial in patients with axSpA in Japan, South Korea and Taiwan. Lumicef met the primary endpoint, and efficacy and safety in patients with axSpA were confirmed in this study.

"Submitting this application for Lumicef for axial spondyloarthritis is a significant step," said Mitsuo Satoh, executive officer, vice president head of R&D Division of Kyowa Kirin, adding: "We believe that Lumicef has the potential to contribute to the health of patients with axSpA."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK